• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
    About Us
  • Pipeline

    Our internally-developed pipeline focuses on the STING pathway and includes our STING agonist, STING antagonist, and STING agonist ADC programs.
    Learn More
  • Science

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
    Details
  • Latest News

      • JUNE 3, 2020
      • 0

      Spring Bank Advances IV SB 11285 Clinical Program

      –      Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) – …

      Read more